• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Clinical Trials

Regeneron touts results of NIH-sponsored EYLEA injection study

March 31, 2021 By Sean Whooley

Regeneron - updated

Regeneron Pharmaceuticals (NSDQ:REGN) announced data supporting the use of its EYLEA injection in NPDR patients. Protocol W, a NIH-sponsored trial to evaluate the EYLEA (aflibercept) injection in patients with moderate to severe non-proliferative diabetic retinopathy (NPDR), without center-involved diabetic macular edema (CI-DME), had its initial results published in JAMA Ophthalmology. At two years, the primary […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals Tagged With: National Institutes of Health, Regeneron

Fractyl enrolls first patient in Revita DMR treatment for Type 2 diabetes

March 22, 2021 By Sean Whooley

Fractyl

Fractyl Laboratories announced today that it enrolled the first patient in the trial for its Revita DMR Type 2 diabetes treatment. The Revita-T2Di trial will evaluate a single Revita DMR treatment to allow patients currently on insulin therapy but with inadequate glycemic control to achieve durable insulin-free glycemic control. The company will seek to use […]

Filed Under: Clinical Trials, Diabetes, Featured Tagged With: fractyllaboratories

Insulet touts results from Omnipod 5 study, expects launch this year

March 22, 2021 By Sean Whooley

Insulet

Insulet (NSDQ:PODD) touted positive results from the first pivotal trial for its Omnipod 5 automated insulin delivery system. Omnipod 5 is the world’s first tubeless, wearable system designed to continuously adapt insulin delivery based on glucose levels and trends, according to a news release. Acton, Mass.-based Insulet said the device, which has FDA breakthrough device […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: Insulet

FDA approves oral multiple sclerosis treatment from J&J’s Janssen unit

March 19, 2021 By Sean Whooley

Updated Janssen logo

Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical announced today that it received FDA approval for its Ponvory treatment. Ponvory (ponesimod) is a once-daily, oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator for treating adults with relapsing forms of multiple sclerosis (MS). It’s areas of treatment include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, […]

Filed Under: Clinical Trials, Featured, Neurological, Pharmaceuticals Tagged With: Janssen Pharmaceuticals, Johnson & Johnson

How Lyra Therapeutics is advancing rhinosinusitis treatment

March 19, 2021 By Sean Whooley

Lyra Therapeutics LYR-210

With the use of anti-inflammatory drugs constituting the standard of care for treating rhinosinusitis, Lyra Therapeutics sees an opportunity. Whatever treatments are out there for the disease in which cavities around the nasal passages are inflamed, they leave room for improvement. “We focused on chronic rhinosinusitis because it’s an area that has been ignored,” Lyra […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Respiratory Tagged With: Lyra Therapeutics

Eyenovia touts study of pupil dilation treatment

March 17, 2021 By Sean Whooley

Eyenovia - updated logo

Eyenovia (NSDQ:EYEN) today announced positive results from a study of its microdose array print (MAP) pupil dilation technology. Study data, published in Therapeutic Delivery, revealed pooled results from two prospective, double-masked, controlled, cross-over superiority Phase 3 studies. Those results concluded that a micro-dosed fixed-combination of tropicamide 1% and phenylephrine 2.5% for pupil dilation (mydriasis) is safe and […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals Tagged With: Eyenovia Inc.

Oramed reaches 25% randomization in oral insulin trial, expects topline results in 2022

March 17, 2021 By Sean Whooley

Oramed

Oramed Pharmaceuticals (NSDQ:ORMP) announced that it reached 25% randomization in the enrollment for its oral insulin capsule trial. New York-based Oramed’s Phase 3 ORA-D-013-1 study for the ORMD-0801 oral insulin capsule for the treatment of Type 2 diabetes has planned for 675 patients overall, reaching a quarter of that mark in enrollment so far with […]

Filed Under: Clinical Trials, Diabetes, Featured, Pharmaceuticals Tagged With: oramedpharmaceuticals

HTX Urology set to participate in study for Urotronic’s prostate treatment device

March 16, 2021 By Sean Whooley

Urotronic

Urotronic announced that HTX Urology is participating in an FDA-cleared study for a minimally invasive device for treating enlarged prostates. Plymouth, Minn.-based Urotronic’s Optilume BPH (benign prostatic hyperplasia, otherwise known as enlarged prostate) catheter system is an outpatient procedure designed to combine balloon dilation to open the prostate and local drug delivery to maintain symptom […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured Tagged With: HTX Urology, urotronic

How Bionaut Labs aims to tackle brain tumors with microrobots

March 15, 2021 By Brian Buntz

Bionaut Labs

The roboticist Michael Shpigelmacher was one of the founders of PrimeSense, a robotic 3-D vision technology company Apple acquired in 2013. PrimeSense created technology empowering the Microsoft Xbox Kinect and the iPhone’s Face ID feature, allowing users to use facial recognition to unlock their phones.  Now Shpigelmacher has set his sights on drug-delivery with Bionaut […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Funding Roundup, Neurological, Oncology, Surgical, Technology Tagged With: 510(k), Bionaut Labs, glioma, Michael Shpigelmacher, Microsoft Kinect, neurology, oncology, PrimeSense

AVEO to collaborate with Bristol Myers Squibb on renal cell carcinoma drugs

March 12, 2021 By Sean Whooley

AVEO Oncology Bristol Myers Squibb

AVEO Oncology (NSDQ:AVEO) announced today that it entered into a clinical trial collaboration with Bristol Myers Squibb. Boston-based AVEO’s collaboration and supply agreement with Bristol Myers Squibb is slated to evaluate Fotivda (tivozanib) in combination with Opdivo (nivolumab), an anti-PD-1 therapy developed by Bristol Myers Squibb. The drugs will be evaluated in a pivotal Phase […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Oncology, Pharmaceuticals Tagged With: AVEO Oncology, Bristol-Myers Squibb Co.

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Interim pages omitted …
  • Go to page 74
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS